Changes in Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study (EscaFlor)

January 29, 2020 updated by: Centre Hospitalier Universitaire de Nīmes

Changes in Cutaneous, Digestive and Urinary Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study

The main objective of this study is to characterize the evolution (over a period of 28 days) of superficial and deep bacterial skin flora in patients with stage 3 or 4 sacral pressure ulcers (bedsores). Changes in terms of pathogenic, potentially pathogenic and non-pathogenic bacterial species at the intra-individual and population levels.

Study Overview

Detailed Description

The secondary objectives of this study are:

A. To compare bacterial communities collected from superficial versus deep samples of stage 3 or 4 sacral bedsores using metagenomics and standard culturing methods.

B. To characterize the evolution of digestive bacterial flora in the same patients over a period of 28 days. Changes in terms of pathogenic, potentially pathogenic and non-pathogenic will be described, as well as the appearance of resistance phenotypes.

C. To characterize the evolution of urinary bacterial flora in the same patients over a period of 28 days. Changes in terms of pathogenic, potentially pathogenic and non-pathogenic will be described, as well as the appearance of resistance phenotypes.

Study Type

Observational

Enrollment (Actual)

55

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Montpellier, France, 34090
        • Centre Mutualiste Neurologique Propara
      • Nîmes, France, 30000
        • Laboratoire d'Etude et de Recherche en Environnement et Santé, Unité Biodiagnostic, UNIMES
      • Nîmes Cedex 2, France, 30908
        • Unité U1047 "Bacterial virulence and infectious diseases", UFR de Médecine
      • Nîmes Cedex 9, France, 30029
        • CHRU de Nîmes - Hôpital Universitaire Carémeau

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The study population consists of patients hospitalized in the Propara neurological rehabilitation (Montpellier, France) having at least one stage 3 or 4 bedsore in the pelvic region.

Description

Inclusion Criteria:

  • The patient was correctly informed about study implementation, its objectives, constraints and patient rights
  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is available for 28 days of follow-up
  • The patient has one or more pelvic pressure ulcers (bedsores)(stage 3 or 4 only). Note: Patients with bedsores of varying stage will be included for the wound corresponding to the highest stage. If the patient has multiple bedsores of the same stage, the deepest wound will be selected.
  • The patient requires a modern wound dressings (i.e. not tulle or gauze) without added bactericidal or antibiotic elements
  • The patient is hospitalized ant the Propara neurological rehabilitation center (Montpellier, France)
  • The patient has not received antibiotics in the last 14 days.

Exclusion Criteria:

  • The patient is participating in another study, or has participated in another study in the last 3 months
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • The patient is pregnant, parturient, or breastfeeding
  • The patient is already included in the present study
  • The patient has sacral pressure ulcers of only stages 1 or 2, or does not have a sacral pressure ulcer
  • Patient under curative anticoagulation
  • Patient who received antibiotics within 14 days before inclusion (however, after inclusion, the patient can be treated with antibiotics if necessary)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
The study population

The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur.

For a description of the study population, see the inclusion/exclusion criteria.

Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample

Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 & 28)
Stool samples will be collected on days 0 and 28.
Urine samples will be collected on days 0 and 28.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
List of pathogenic, potentially pathogenic and commensal bacterial species in superficial and deep bedsore samples
Time Frame: Baseline (day 0)
At the individual level
Baseline (day 0)
List of pathogenic, potentially pathogenic and commensal bacterial species in superficial and deep bedsore samples
Time Frame: Day 28
At the individual level
Day 28
Percentage of pathogenic, potentially pathogenic, and commensal bacterial species in superficial and deep bedsore samples
Time Frame: baseline (day 0)
Calculated over the entire study population
baseline (day 0)
Percentage of pathogenic, potentially pathogenic, and commensal bacterial species in superficial and deep bedsore samples
Time Frame: Day 28
Calculated over the entire study population
Day 28

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Classification of bacteria present according to respiratory type, gram negative/positive, shape, and resistance phenotypes.
Time Frame: baseline (Day 0)
Based on superficial and deep bedsore samples.
baseline (Day 0)
Classification of bacteria present according to respiratory type, gram negative/positive, shape, and resistance phenotypes.
Time Frame: Day 28
Based on superficial and deep bedsore samples.
Day 28
List of pathogenic, potentially pathogenic and commensal bacterial species in stool samples
Time Frame: baseline (day 0)
baseline (day 0)
List of pathogenic, potentially pathogenic and commensal bacterial species in stool samples
Time Frame: Day 28
Day 28
List of pathogenic, potentially pathogenic and commensal bacterial species in urine samples
Time Frame: baseline (day 0)
baseline (day 0)
List of pathogenic, potentially pathogenic and commensal bacterial species in urine samples
Time Frame: day 28
day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Catherine Dunyach-Remy, PhD, Centre Hospitalier Universitaire de Nīmes

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 11, 2015

Primary Completion (ACTUAL)

September 21, 2017

Study Completion (ACTUAL)

September 21, 2017

Study Registration Dates

First Submitted

February 4, 2014

First Submitted That Met QC Criteria

February 4, 2014

First Posted (ESTIMATE)

February 5, 2014

Study Record Updates

Last Update Posted (ACTUAL)

January 30, 2020

Last Update Submitted That Met QC Criteria

January 29, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LOCAL/2013/CDR-01
  • 2014-A00534-43 (OTHER: RCB number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bedsore

Clinical Trials on 3mm tissue punch biopsy

Subscribe